Download App

Log in to access Online Inquiry
Company Overview More
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
CEO: Azamian M.D., Bobak R.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TARS Tarsus Pharmaceuticals

14.060-0.430-2.97%
Close 05/26 20:00 ET
High
14.695
Open
14.440
Turnover
1.80M
Low
13.590
Pre Close
14.490
Volume
127.00K
Market Cap
370.17M
P/E(TTM)
Loss
52wk High
39.080
Shares
26.33M
P/E(Static)
Loss
52wk Low
10.800
Float Cap
151.84M
Bid/Ask %
-75.00%
Historical High
63.690
Shs Float
10.80M
Volume Ratio
0.82
Historical Low
10.800
Dividend TTM
--
Div Yield TTM
--
P/B
2.48
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.18%
Amplitude
7.63%
Avg Price
14.197
Lot Size
1
Float Cap
151.84M
Bid/Ask %
-75.00%
Historical High
63.690
Shs Float
10.80M
Volume Ratio
0.82
Historical Low
10.800
Dividend TTM
--
P/B
2.48
Dividend LFY
--
Turnover Ratio
1.18%
Amplitude
7.63%
Avg Price
14.197
Lot Size
1
Price Forecast

No Data

News

Comment